Authors' objectives: 1. What is the clinical effectiveness of hip protectors to prevent hip fractures for residents of LTC and assisted or supervised care facilities?2. What is the cost-effectiveness of hip protectors to prevent hip fractures for residents of LTC and assisted or supervised care facilities?3. What are the guidelines and criteria for patient selection for use of hip protectors?

Authors' recommendations: Hip protectors appear to be effective at reducing the risk of hip fractures in LTC facility residents, with a relative risk of 0.77. Our primary economic evaluation suggests that if the available options are hip protectors, alendronate, alendronate plus hip protectors, and no treatment, a combination of alendronate and hip protectors causes the greatest reduction in disease burden and would be considered cost effective compared to alendronate if a decisionmaker is willing to pay up to CAN$50,000 for a quality-adjusted life-year in women between 75 and 89 with a previous fracture. Compared to no intervention, hip protectors are a cost-effective treatment option (based on a willingness to pay of CAN$50,000/QALY) for women over 70 years of age living in LTC facilities.

Authors' methods: Review

Project Status: Completed

Year Published: 2008

URL for published report: https://www.cadth.ca/sites/default/files/pdf/I3015_Hip_Protectors_Long_Term_Care_tr_e.pdf

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Canada

Organisation Name: Canadian Agency for Drugs and Technologies in Health

Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;

Contact Name: requests@cadth.ca

Contact Email: requests@cadth.ca

Copyright: Canadian Agency for Drugs and Technologies in Health (CADTH)